Skip to content

Clinico-demographic Features of Patients With Acne Vulgaris

Clinico-demographic Features of Patients With Acne Vulgaris

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05061615
Enrollment
150
Registered
2021-09-29
Start date
2021-10-01
Completion date
2022-10-31
Last updated
2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

The Global Burden of Disease Study 2010 found that acne vulgaris is the eight most common skin disease, with an estimated global prevalence (for all ages) of 9.38%.(1) Furthermore . Acne is a chronic inflammatory process that presents with two types of lesions clinically; non-inflammatory (closed and open) and inflammatory lesions (papules ,pustules ,nodules and post inflammatory pigmentary changes).

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Days to 35 Years

Inclusion criteria

* patients of both sexes with clinical evident acne vulgaris * any age

Exclusion criteria

* no

Design outcomes

Primary

MeasureTime frameDescription
Body mass indexone year(weight (kg)/height(m)2)
severity of acne vulgarisOne yearGlobal acne grading system (GAGS): The GAGS is an acne grading system developed by Doshi et al . (13) In this grading system, lesions of acne vulgaris are divided into six sites: the forehead, right cheek, left cheek, nose, chin, and chest back.Each site has one factor score: the chin and nose are graded by one factor, the forehead and each cheek are graded by two factors and the chest and back are graded by three factors. Lesions are scored as follows: one point for a comedone, two points for a papule, three points for a pustule, and four points for a nodule. The lesion score of each site is calculated by the factor score, and the final score for that site is obtained. The total score varies between 1 and 44 and is evaluated as follows: mild falls between 1 and 18, moderate falls between 19 and 30, severe falls between 31 and 38, and very severe is over 39.

Countries

Egypt

Contacts

Primary ContactDoaa S Abdelkhalek, resident
doaa_saad_post@med.sohag.edu.eg01065800272
Backup ContactEssam E Abd-El Aziz, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026